Abbott Drug Launch Could Hurt Profit
Abbott Laboratories Inc., which cheered Wall Street on New Year’s Eve with news of earlier-than-expected U.S. marketing approval for its rheumatoid arthritis drug, said the cost of launching Humira will clip its outlook for 2003 profit.
Humira should bring in revenue of more than $150 million in its first year on the market, assuming it also gets widely expected European marketing approval in mid-2003, Abbott executives told analysts and reporters.
But the sales will come at a price. Abbott said the cost of launching the drug will affect its 2003 profit outlook, but declined to give details.
Abbott shares rose 5 cents to $40.05 on the NYSE.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
